Beovu (brolucizumab-dbll) / Novartis, Santen, China Medical System - LARVOL DELTA

Intraocular Cytokine Level Prediction from Fundus Images and Optical Coherence Tomography. (PubMed, Sensors (Basel)) - "Diseases included 64 exudative age-related macular degeneration, 29 brolucizumab-associated endophthalmitis, 19 cataract surgeries, 15 retinal vein occlusion, and 8 diabetic macular edema...No significant difference was observed between CFP and OCT (p = 0.9281). Notably, VEGF showed low predictability (31st with CFP, 12th with OCT)."

Journal • Age-related Macular Degeneration • Cataract • Diabetic Macular Edema • Macular Degeneration • Ocular Infections • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion • Wet Age-related Macular Degeneration

Use of brolucizumab in refractory neovascular age-related macular degeneration: characteristics and biomarkers of intraocular inflammation from an Asian real-world study. (PubMed, Jpn J Ophthalmol) - "Vigilant examination after the initial brolucizumab injections is critical. Patients with identified risk factors may need meticulous monitor following brolucizumab injections."

Biomarker • Journal • Real-world evidence • Age-related Macular Degeneration • Inflammation • Macular Degeneration • Ocular Inflammation • Ophthalmology • Retinal Disorders • Uveitis • Vasculitis • Wet Age-related Macular Degeneration

Factors associated with patient-initiated discontinuation of anti-vascular endothelial growth factor therapy for diabetic macular edema: a real-world study in Japan. (PubMed, Jpn J Ophthalmol) - "The findings of this study underscore the importance of individualized patient management strategies to enhance long-term adherence to anti-VEGF therapy among patients with DME."

Journal • Real-world evidence • Diabetic Macular Edema • Ophthalmology

SPARROW: Comparison of Rapid Aflibercept and Brolucizumab T&E in wAMD (clinicaltrials.gov) - P=N/A | N=80 | Active, not recruiting | Sponsor: Berner Augenklinik | Enrolling by invitation ➔ Active, not recruiting

Enrollment closed • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Faricimab treat-and-extend approach for neovascular age-related macular degeneration: insights from real-world clinical practice. (PubMed, Int J Retina Vitreous) - "The switch to faricimab in a T&E regimen significantly increased treatment intervals maintaining BCVA in patients with nAMD under other anti-VEGF treatments. No serious adverse events were reported. Longer follow-up is needed to confirm these results."

Journal • Real-world evidence • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Significant Correlation Between Choroidal Thickness and Decrease in Choroidal Blood Flow After Switching to Brolucizumab for Refractory Neovascular Age-Related Macular Degeneration. (PubMed, Ophthalmol Ther) - "IVBr is associated with significant reductions in CRT and SFCT and may decrease choroidal blood flow, particularly in older patients and those with thinner SFCTs."

Journal • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Cost-Effectiveness of Vascular Endothelial Growth Factor Inhibitors in the Management of Wet Age-Related Macular Degeneration: A Systematic Review. (PubMed, Value Health Reg Issues) - "Decision making in wAMD treatment requires more thorough economic evaluations that incorporate standardized methodologies and lengthy cost assessments."

HEOR • Journal • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Drug-induced immune-mediated uveitis: a real-world pharmacovigilance analysis using FAERS and JADER databases. (PubMed, BMJ Open Ophthalmol) - "Our study highlights the diverse range of drugs implicated in the occurrence or progression of IMU. These findings emphasise the need for early risk assessment, careful monitoring and positive intervention in managing treatments involving high-risk drugs. Future research should focus on elucidating underlying mechanisms and risk factors to develop safer therapeutic strategies."

Adverse events • Journal • Real-world evidence • Retrospective data • Inflammation • Musculoskeletal Diseases • Ocular Inflammation • Oncology • Ophthalmology • Uveitis

Computational modeling of anti-VEGFA drug interactions with VEGF-A: Insights into therapeutic strategies for neovascular AMD. (PubMed, Comput Biol Chem) - "In this study, we performed the first integrated in silico evaluation of six clinically relevant anti-VEGF drugs: abicipar, aflibercept, bevacizumab, brolucizumab, faricimab, and ranibizumab. This systematic analysis highlights the coexistence of evolutionary conservation and rational molecular engineering as complementary strategies shaping anti-VEGF drug performance. Overall, our findings demonstrate that computational modeling offers a cost-effective and predictive tool to guide the optimization of current therapies and the rational design of next-generation anti-VEGF agents for nAMD and other retinal vascular disorders."

Journal • Age-related Macular Degeneration • Cardiovascular • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

BLUE SKY: Observational Study to Evaluate Fluid Resolution and Effectiveness in Patients Receiving Beovu in Neovascular Age-related Macular Degeneration and Visual Impairment Due to Diabetic Macular Edema (clinicaltrials.gov) - P=N/A | N=572 | Completed | Sponsor: Novartis Pharmaceuticals | Active, not recruiting ➔ Completed

Trial completion • Age-related Macular Degeneration • Diabetic Macular Edema • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Effectiveness, Safety, and Real-World Experience of Brolucizumab: A Systematic Review. (PubMed, Pharmaceuticals (Basel)) - "Non-inferior vision outcomes and superior fluid resolution have been demonstrated. However, it carries a distinct risk of IOI and occlusive vasculitis, necessitating careful patient selection, dosing, and monitoring."

Journal • Real-world evidence • Review • Age-related Macular Degeneration • Diabetic Macular Edema • Inflammation • Macular Degeneration • Ocular Inflammation • Ophthalmology • Pediatrics • Retinal Disorders • Vasculitis • Wet Age-related Macular Degeneration

Predictive value of uninterrupted dry macula duration for discontinuation of anti-VEGF therapy in diabetic macular edema. (PubMed, Sci Rep) - "Data were collected from 15 Japanese DME patients who completed two years of brolucizumab or aflibercept treatment in the KESTREL phase III trials and were followed for ≥ 3 years...Maintaining long-term uninterrupted dry macula with anti-VEGF agents may be associated with treatment discontinuation in DME. Confirmation in larger prospective studies would be warranted."

Journal • Retrospective data • Diabetic Macular Edema • Ophthalmology

Increased aqueous flare after intravitreal brolucizumab injections compared to aflibercept in neovascular age-related macular degeneration. (PubMed, Graefes Arch Clin Exp Ophthalmol) - "In nAMD, aqueous flare values were higher in brolucizumab-treated eyes and increased with age but were unaffected by the number of injections. Different flare values of each drug might affect the aqueous flare values within hours after injection."

Journal • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Twelve-Month Outcomes of Brolucizumab in Routine Clinical Practice: Fight Retinal Blindness! Registry. (PubMed, Clin Exp Ophthalmol) - "Eyes that switched from a first generation VEGF inhibitor to brolucizumab in routine clinical practice achieved a clinically significant extension of their treatment interval, with more than a third becoming inactive but with a relatively high rate of IOI."

Journal • Age-related Macular Degeneration • Inflammation • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Short-term efficacy and safety of intravitreal brolucizumab in diabetic macular edema: A retrospective interventional study. (PubMed, Oman J Ophthalmol) - "The study findings in this cohort demonstrated statistically significant improvement in BCVA and a substantial decrease in SFMT. However, more real-world studies are required to enhance the validation of this study's findings."

Journal • Retrospective data • Cardiovascular • Diabetic Macular Edema • Inflammation • Ophthalmology

Predictive factors for the efficacy of brolucizumab in refractory polypoidal choroidal vasculopathy following aflibercept resistance. (PubMed, PLoS One) - "Eyes without marked early choroidal thinning (<40% CCT reduction at A1) were more likely to extend, whereas marked thinning (≥40%) signaled difficulty extending under T&E regimen after switching to brolucizumab. Given the small sample and few events, estimates should be interpreted cautiously and considered hypothesis-generating, and warrant prospective external validation studies."

Biomarker • Journal • Observational data • Retrospective data • Age-related Macular Degeneration

Single-arm prospective trial of efficacy and safety of Brolucizumab 6mg with longer loading interval (q6w) in Chinese patients with naive polypoidal choroidal vasculopathy (PCV) (ChiCTR) - P4 | N=80 | Not yet recruiting | Sponsor: Peking Union Medical College Hospital; Peking Union Medical College Hospital

New P4 trial • Age-related Macular Degeneration • Retinal Disorders

Conbercept Treatment for Heart-Shaped Vascular Intertwined Nets in Macular Neovascularization: Anti-VEGF Drug Therapy Strategy Based on Vascular Geometry Diagnosed by OCTA. (PubMed, Clin Case Rep) - "Anti-VEGF therapies, such as Aflibercept (Eylea), Bevacizumab (Avastin), Brolucizumab (Beovu), Conbercept (Lumitin), Faricimab (Vabysmo), Ranibizumab (Lucentis), and Pegaptanib (Macugen), have significantly transformed MNV management, targeting VEGF to curb this pathological vascular growth. Conbercept, in particular, proved effective against the complex intertwined nets observed in this patient. These findings emphasize the promise of individualized treatment strategies and the potential of OCTA-based vascular geometry classification as a tool for precision medicine."

Journal • Age-related Macular Degeneration • Cardiovascular • Diabetes • Hypertension • Macular Degeneration • Metabolic Disorders • Mood Disorders • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Brolucizumab for Diabetic Macular Edema in Participants With/Without Prior Anti-VEGF Exposure: KINGFISHER Study Post Hoc Analysis. (PubMed, Ophthalmol Retina) - "These results demonstrate the effectiveness of brolucizumab 6 mg irrespective of the prior treatment status of the participants."

Journal • Retrospective data • Diabetic Macular Edema • Diabetic Retinopathy • Inflammation • Ophthalmology • Retinal Disorders

Efficacy and Safety of Intravitreal Brolucizumab in Chronic Central Serous Chorioretinopathy: A Retrospective Cohort Study [Letter]. (PubMed, Clin Ophthalmol) - No abstract available

Journal • Retrospective data • Retinal Disorders

Cost-effectiveness analysis of Brolucizumab compared to Aflibercept and Ranibizumab in nAMD with persistent retinal fluid. (PubMed, Eur J Ophthalmol) - "Purpose of the researchThis study aimed to evaluate the cost-effectiveness of Brolucizumab in patients with exudative age-related macular degeneration (AMD) and persistent retinal fluid unresponsive to previous therapies, within the context of a real-world clinical practice setting in a Spanish referral hospital. Additionally, the analysis indicated a 43% probability of transitioning to Faricimab within the studied population.ConclusionsBrolucizumab was determined to be not cost-effective compared to Ranibizumab and Aflibercept in patients with exudative AMD and persistent retinal fluid, primarily due to a higher number of follow-up visits necessitated by its safety profile. Furthermore, newly observed vitreous opacities and a tendency towards the use of Faricimab were noted."

HEOR • Journal • Age-related Macular Degeneration • Macular Degeneration • Ocular Infections • Ocular Inflammation • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Capsid engineering of novel AAV variants enabling gene delivery in choroid (ESGCT 2024) - "Implementation of anti-angiogenic drugs like aflibercept or brolucizumab has improved the prognosis of neovascular AMD...Our study identified that new AAV1-based capsid variants can transduce choroid efficiently, which can be confirmed by in vitro, in vivo, and human ex vivo culture. Our results showed that novel AAV1-based capsids hold high potential to be a valuable tool for the management of AMD in the future."

Age-related Macular Degeneration • Gene Therapies • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Efficacy and Safety of Intravitreal Brolucizumab in Chronic Central Serous Chorioretinopathy: A Retrospective Cohort Study [Response to Letter]. (PubMed, Clin Ophthalmol) - No abstract available

Journal • Retrospective data • Retinal Disorders

Anti-vascular endothelial growth factor therapies in ophthalmology. (PubMed, Med Hypothesis Discov Innov Ophthalmol) - "Keywords used in the search strategy included terms such as "anti-VEGF therapy", "biosimilar pharmaceuticals", "intravitreal and intrastromal anti-VEGF injections", "retinal diseases" including "macular degeneration" and "retinal neovascularization", "ranibizumab", and "bevacizumab", as well as relevant MeSH terms where applicable...Newer agents such as brolucizumab and faricimab offer prolonged durability and enhanced anatomic outcomes, while biosimilars provide cost-effective alternatives...Anti-VEGF therapies have revolutionized the field of ophthalmology, providing sight-saving treatment for a range of retinal diseases that were once considered untreatable or inevitably blinding. Today, anti-VEGF drugs are the go-to option for managing neovascular retinal disorders, thanks to their proven efficacy, favorable safety profile, and transformative impact on modern eye care."

Journal • Review • Age-related Macular Degeneration • Diabetic Macular Edema • Diabetic Retinopathy • Genetic Disorders • Glaucoma • Hematological Disorders • Inherited Retinal Dystrophy • Macular Degeneration • Ocular Inflammation • Oncology • Ophthalmology • Retinal Disorders • Retinal Vein Occlusion • Retinitis Pigmentosa • Retinopathy of Prematurity • Uveitis • Wet Age-related Macular Degeneration • PRPH

Twelve-Month Outcomes of Anti-VEGF Therapy for nAMD with Brolucizumab, Aflibercept, and Ranibizumab in the Polish National Registry: A Multicenter Database Study. (PubMed, J Clin Med) - "Only ~22% achieved at least 0.3 logMAR improvement, underscoring real-world treatment challenges. System-level support, appropriate treatment intensification, and strategic use of newer, durable agents like brolucizumab are crucial to narrowing the gap between clinical trial efficacy and real-world effectiveness, ultimately improving long-term outcomes in nAMD care."

Journal • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration